BACKGROUND: Recent studies have demonstrated that Th2 responses have the ability to antagonize Th17 responses. In mouse models of allergic asthma, blockade of Th2-effector cytokines results in elaboration of Th17 responses and associated increases in pulmonary neutrophilia. While these can be controlled by simultaneous blockade of Th17-associated effector cytokines, clinical trials of anti-IL-17/IL-17RA blocking therapies have demonstrated increased of risk of bacterial and fungal infections. Identification of minimally effective doses of cytokine-blocking therapies with the goal of reducing the potential emergence of infection-related complications is a translationally relevant goal. OBJECTIVE: In the current report, we examine whether combined blockade of IL-13 and IL-17A, at individually sub-therapeutic levels, can limit the development of allergic asthma while sparing expression of IL-17A-associated anti-microbial effectors. METHODS: House dust mite was given intratracheally to A/J mice. Anti-IL-13 and anti-IL-17A antibodies were administered individually, or concomitantly at sub-therapeutic doses. Airway hyper-reactivity, lung inflammation, magnitude of Th2- and Th17-associated cytokine production and expression of IL-13- and IL-17A-induced genes in the lungs was assessed. RESULTS: Initial dosing studies identified sub-therapeutic levels of IL-13 and IL-17A blocking mAbs that have a limited effect on asthma parameters and do not impair responses to microbial products or infection. Subsequent studies demonstrated that combined sub-therapeutic dosing with IL-13 and IL-17A blocking mAbs resulted in significant improvement in airway hyperresponsiveness (AHR) and expression of IL-13-induced gene expression. Importantly, these doses neither exacerbated nor inhibited production of Th17-associated cytokines, or IL-17A-associated gene expression. CONCLUSION: This study suggests that combining blockade of individual Th2 and Th17 effector cytokines, even at individually sub-therapeutic levels, may be sufficient to limit disease development while preserving important anti-microbial pathways. Such a strategy may therefore have reduced potential for adverse events associated with blockade of these pathways.
BACKGROUND: Recent studies have demonstrated that Th2 responses have the ability to antagonize Th17 responses. In mouse models of allergic asthma, blockade of Th2-effector cytokines results in elaboration of Th17 responses and associated increases in pulmonary neutrophilia. While these can be controlled by simultaneous blockade of Th17-associated effector cytokines, clinical trials of anti-IL-17/IL-17RA blocking therapies have demonstrated increased of risk of bacterial and fungal infections. Identification of minimally effective doses of cytokine-blocking therapies with the goal of reducing the potential emergence of infection-related complications is a translationally relevant goal. OBJECTIVE: In the current report, we examine whether combined blockade of IL-13 and IL-17A, at individually sub-therapeutic levels, can limit the development of allergic asthma while sparing expression of IL-17A-associated anti-microbial effectors. METHODS: House dust mite was given intratracheally to A/J mice. Anti-IL-13 and anti-IL-17A antibodies were administered individually, or concomitantly at sub-therapeutic doses. Airway hyper-reactivity, lung inflammation, magnitude of Th2- and Th17-associated cytokine production and expression of IL-13- and IL-17A-induced genes in the lungs was assessed. RESULTS: Initial dosing studies identified sub-therapeutic levels of IL-13 and IL-17A blocking mAbs that have a limited effect on asthma parameters and do not impair responses to microbial products or infection. Subsequent studies demonstrated that combined sub-therapeutic dosing with IL-13 and IL-17A blocking mAbs resulted in significant improvement in airway hyperresponsiveness (AHR) and expression of IL-13-induced gene expression. Importantly, these doses neither exacerbated nor inhibited production of Th17-associated cytokines, or IL-17A-associated gene expression. CONCLUSION: This study suggests that combining blockade of individual Th2 and Th17 effector cytokines, even at individually sub-therapeutic levels, may be sufficient to limit disease development while preserving important anti-microbial pathways. Such a strategy may therefore have reduced potential for adverse events associated with blockade of these pathways.
Authors: S P Hogan; A W Mould; J M Young; M E Rothenberg; A J Ramsay; K Matthaei; I G Young; P S Foster Journal: Immunol Cell Biol Date: 1998-10 Impact factor: 5.126
Authors: Dawn C Newcomb; Madison G Boswell; Matthew M Huckabee; Kasia Goleniewska; Daniel E Dulek; Sara Reiss; Nicholas W Lukacs; Jay K Kolls; R Stokes Peebles Journal: J Immunol Date: 2011-12-30 Impact factor: 5.422
Authors: H Maarsingh; B G J Dekkers; A B Zuidhof; I S T Bos; M H Menzen; T Klein; G Flik; J Zaagsma; H Meurs Journal: Eur Respir J Date: 2011-02-10 Impact factor: 16.671
Authors: Dawn C Newcomb; Weisong Zhou; Martin L Moore; Kasia Goleniewska; Gurjit K K Hershey; Jay K Kolls; R Stokes Peebles Journal: J Immunol Date: 2009-05-01 Impact factor: 5.422
Authors: Stephane Lajoie; Ian P Lewkowich; Yusuke Suzuki; Jennifer R Clark; Alyssa A Sproles; Krista Dienger; Alison L Budelsky; Marsha Wills-Karp Journal: Nat Immunol Date: 2010-08-29 Impact factor: 25.606
Authors: Brandon W Lewis; Stephanie A Amici; Hye-Young Kim; Emily M Shalosky; Aiman Q Khan; Joshua Walum; Kymberly M Gowdy; Joshua A Englert; Ned A Porter; Mitchell H Grayson; Rodney D Britt; Mireia Guerau-de-Arellano Journal: J Immunol Date: 2022-03-14 Impact factor: 5.426
Authors: I Lewkowich; R Ahlbrand; E Johnson; J McAlees; N Nawreen; R Raman; I Lingel; J Hargis; C Hoover; R Sah Journal: Brain Behav Immun Date: 2020-05-04 Impact factor: 7.217
Authors: Siti Farah Rahmawati; Maurice Te Velde; Huib A M Kerstjens; Alexander S S Dömling; Matthew Robert Groves; Reinoud Gosens Journal: Front Allergy Date: 2021-08-30